 Margaret Macy
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 8 | 2023 | 133 | 2.340 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 1356 | 1.070 |
Why?
| | Neoplasms | 13 | 2023 | 2088 | 0.960 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2022 | 660 | 0.870 |
Why?
| | Protein Kinase Inhibitors | 5 | 2023 | 784 | 0.760 |
Why?
| | Glycolipids | 1 | 2021 | 35 | 0.750 |
Why?
| | Central Nervous System Neoplasms | 2 | 2019 | 125 | 0.720 |
Why?
| | Glioma | 4 | 2022 | 285 | 0.710 |
Why?
| | Radiation Injuries | 2 | 2019 | 128 | 0.680 |
Why?
| | Indazoles | 2 | 2022 | 57 | 0.660 |
Why?
| | Bevacizumab | 2 | 2019 | 114 | 0.650 |
Why?
| | Benzamides | 2 | 2022 | 168 | 0.640 |
Why?
| | Astrocytoma | 2 | 2017 | 106 | 0.630 |
Why?
| | Brain Stem Neoplasms | 2 | 2017 | 84 | 0.630 |
Why?
| | Radiotherapy | 1 | 2019 | 175 | 0.610 |
Why?
| | Chemoradiotherapy | 2 | 2017 | 187 | 0.600 |
Why?
| | Brain Diseases | 1 | 2019 | 124 | 0.600 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2022 | 224 | 0.580 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 213 | 0.580 |
Why?
| | Brain Neoplasms | 5 | 2022 | 966 | 0.490 |
Why?
| | Sarcoma | 2 | 2015 | 137 | 0.460 |
Why?
| | Child, Preschool | 20 | 2023 | 9120 | 0.420 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2023 | 850 | 0.410 |
Why?
| | Child | 30 | 2023 | 18408 | 0.410 |
Why?
| | Biomarkers, Tumor | 4 | 2022 | 1032 | 0.380 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2012 | 62 | 0.370 |
Why?
| | Quinazolines | 2 | 2023 | 240 | 0.360 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2010 | 23 | 0.360 |
Why?
| | Prognosis | 9 | 2023 | 3315 | 0.350 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 1875 | 0.350 |
Why?
| | Adolescent | 22 | 2023 | 17811 | 0.340 |
Why?
| | Glioblastoma | 1 | 2012 | 250 | 0.330 |
Why?
| | Piperidines | 1 | 2010 | 159 | 0.320 |
Why?
| | Leukemia | 1 | 2010 | 208 | 0.300 |
Why?
| | DNA Damage | 1 | 2010 | 351 | 0.300 |
Why?
| | Liver Neoplasms | 1 | 2012 | 504 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2019 | 637 | 0.280 |
Why?
| | 3-Iodobenzylguanidine | 2 | 2023 | 6 | 0.260 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1519 | 0.250 |
Why?
| | Humans | 38 | 2023 | 114077 | 0.250 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 256 | 0.250 |
Why?
| | Camptothecin | 2 | 2017 | 96 | 0.250 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 959 | 0.240 |
Why?
| | Sirolimus | 2 | 2016 | 181 | 0.220 |
Why?
| | Survival Rate | 5 | 2019 | 1638 | 0.210 |
Why?
| | Pediatrics | 2 | 2020 | 981 | 0.210 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2023 | 437 | 0.200 |
Why?
| | Osteosarcoma | 1 | 2023 | 65 | 0.200 |
Why?
| | Infant | 10 | 2023 | 7945 | 0.200 |
Why?
| | Male | 22 | 2021 | 55418 | 0.200 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 140 | 0.200 |
Why?
| | Antibodies, Monoclonal | 3 | 2016 | 1257 | 0.190 |
Why?
| | Gangliosides | 1 | 2021 | 18 | 0.190 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4392 | 0.190 |
Why?
| | Female | 22 | 2021 | 59347 | 0.190 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1162 | 0.190 |
Why?
| | Whole Genome Sequencing | 1 | 2021 | 94 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2014 | 1837 | 0.180 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2023 | 328 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2023 | 191 | 0.180 |
Why?
| | Salvage Therapy | 2 | 2019 | 127 | 0.180 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2159 | 0.170 |
Why?
| | Necrosis | 2 | 2019 | 209 | 0.170 |
Why?
| | Maximum Tolerated Dose | 3 | 2018 | 183 | 0.170 |
Why?
| | Receptor, IGF Type 1 | 2 | 2010 | 58 | 0.170 |
Why?
| | Pyridazines | 1 | 2020 | 46 | 0.170 |
Why?
| | Dexamethasone | 2 | 2019 | 316 | 0.160 |
Why?
| | Young Adult | 9 | 2022 | 10458 | 0.160 |
Why?
| | Etoposide | 3 | 2017 | 149 | 0.160 |
Why?
| | Imidazoles | 1 | 2020 | 203 | 0.160 |
Why?
| | Adult | 12 | 2023 | 30394 | 0.160 |
Why?
| | Lymphoma | 1 | 2019 | 176 | 0.150 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 55 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1117 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2019 | 137 | 0.150 |
Why?
| | Taxoids | 1 | 2018 | 93 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 152 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 56 | 0.140 |
Why?
| | Heterocyclic Compounds | 1 | 2017 | 18 | 0.140 |
Why?
| | Glucocorticoids | 2 | 2019 | 526 | 0.140 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2018 | 182 | 0.140 |
Why?
| | Cetuximab | 1 | 2017 | 90 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 519 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2019 | 735 | 0.130 |
Why?
| | Azacitidine | 1 | 2017 | 129 | 0.130 |
Why?
| | Myelodysplastic Syndromes | 1 | 2017 | 119 | 0.120 |
Why?
| | Pilot Projects | 1 | 2019 | 1361 | 0.120 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2017 | 533 | 0.120 |
Why?
| | Thyroxine | 1 | 2014 | 57 | 0.110 |
Why?
| | Hypothyroidism | 1 | 2014 | 65 | 0.110 |
Why?
| | Treatment Outcome | 8 | 2022 | 9050 | 0.110 |
Why?
| | Melanoma | 1 | 2019 | 620 | 0.110 |
Why?
| | Animals | 4 | 2021 | 31570 | 0.110 |
Why?
| | DNA Methylation | 1 | 2017 | 493 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3039 | 0.100 |
Why?
| | Oxides | 1 | 2013 | 40 | 0.100 |
Why?
| | Arsenicals | 1 | 2013 | 23 | 0.100 |
Why?
| | Organoplatinum Compounds | 1 | 2012 | 37 | 0.100 |
Why?
| | Leucovorin | 1 | 2012 | 43 | 0.100 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2022 | 393 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 308 | 0.100 |
Why?
| | Fluorouracil | 1 | 2012 | 152 | 0.100 |
Why?
| | Spinal Cord | 1 | 2014 | 344 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 314 | 0.090 |
Why?
| | HL-60 Cells | 1 | 2010 | 28 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 926 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 74 | 0.090 |
Why?
| | Brain | 2 | 2014 | 2355 | 0.090 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2010 | 80 | 0.090 |
Why?
| | Infant, Newborn | 3 | 2022 | 5038 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 742 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 924 | 0.090 |
Why?
| | Drug Synergism | 1 | 2010 | 315 | 0.080 |
Why?
| | Pons | 1 | 2009 | 30 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 561 | 0.080 |
Why?
| | Methotrexate | 1 | 2010 | 227 | 0.080 |
Why?
| | Recurrence | 2 | 2010 | 925 | 0.080 |
Why?
| | Doxorubicin | 1 | 2010 | 286 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2009 | 496 | 0.080 |
Why?
| | Molecular Targeted Therapy | 2 | 2022 | 347 | 0.080 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 98 | 0.080 |
Why?
| | Acute Disease | 1 | 2010 | 909 | 0.070 |
Why?
| | Cell Cycle | 1 | 2010 | 541 | 0.070 |
Why?
| | Drug Design | 1 | 2008 | 147 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1014 | 0.070 |
Why?
| | Cytarabine | 2 | 2017 | 51 | 0.070 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 271 | 0.070 |
Why?
| | Genomics | 2 | 2022 | 631 | 0.070 |
Why?
| | Medical Oncology | 1 | 2008 | 229 | 0.070 |
Why?
| | Cohort Studies | 3 | 2022 | 4884 | 0.070 |
Why?
| | Risk Assessment | 1 | 2015 | 2958 | 0.070 |
Why?
| | Mice | 1 | 2021 | 14847 | 0.060 |
Why?
| | Disease Progression | 1 | 2012 | 2371 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2012 | 2550 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2010 | 2173 | 0.050 |
Why?
| | Lactams, Macrocyclic | 1 | 2023 | 46 | 0.050 |
Why?
| | Gene Amplification | 1 | 2023 | 95 | 0.050 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2022 | 40 | 0.050 |
Why?
| | Aminopyridines | 1 | 2023 | 81 | 0.050 |
Why?
| | Oncogenes | 1 | 2022 | 104 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 359 | 0.050 |
Why?
| | Apoptosis | 1 | 2010 | 2349 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2022 | 12521 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1611 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2022 | 171 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2022 | 175 | 0.050 |
Why?
| | Drug and Narcotic Control | 1 | 2020 | 29 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 294 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2020 | 159 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 532 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 217 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2022 | 607 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 316 | 0.040 |
Why?
| | Base Sequence | 1 | 2022 | 2114 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 67 | 0.040 |
Why?
| | Precision Medicine | 1 | 2021 | 335 | 0.040 |
Why?
| | Isotretinoin | 1 | 2018 | 22 | 0.040 |
Why?
| | Immunotherapy | 1 | 2022 | 473 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 102 | 0.040 |
Why?
| | Azepines | 1 | 2018 | 69 | 0.040 |
Why?
| | Hematologic Diseases | 1 | 2018 | 55 | 0.040 |
Why?
| | Daunorubicin | 1 | 2017 | 24 | 0.040 |
Why?
| | Blepharoptosis | 1 | 1997 | 6 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 618 | 0.040 |
Why?
| | Benzylamines | 1 | 2017 | 39 | 0.040 |
Why?
| | Genes, Dominant | 1 | 1997 | 93 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2018 | 184 | 0.030 |
Why?
| | Treatment Failure | 1 | 2018 | 330 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1997 | 66 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 78 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2018 | 83 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 182 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 813 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 110 | 0.030 |
Why?
| | Pyrimidines | 1 | 2018 | 374 | 0.030 |
Why?
| | SEER Program | 1 | 2015 | 195 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 2886 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2090 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 517 | 0.030 |
Why?
| | United States | 2 | 2022 | 12144 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1131 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2248 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 3338 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 1218 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 241 | 0.020 |
Why?
| | Radiography | 1 | 2014 | 803 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6198 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2273 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 281 | 0.020 |
Why?
| | Radiosurgery | 1 | 2009 | 299 | 0.020 |
Why?
| | Quality of Life | 1 | 2009 | 2344 | 0.010 |
Why?
| | Lod Score | 1 | 1997 | 65 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 1997 | 176 | 0.010 |
Why?
| | Genetic Markers | 1 | 1997 | 320 | 0.010 |
Why?
| | Pedigree | 1 | 1997 | 460 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1997 | 486 | 0.010 |
Why?
| | Genotype | 1 | 1997 | 1757 | 0.010 |
Why?
|
|
Macy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|